Form 4 for ELVN Enliven Therapeutics, Inc.

Accepted 2025-05-05 00:00:00 ET · period of report 2025-05-01 · accession 0001415889-25-012030 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2025-05-05	2025-05-01+	ELVN	Kintz Samuel	Pres AND CEO, Dir	S - Sale	$20.06	-7,500	980.1K	-0.8%	-$150.4K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-05-02	S	D	2,170	$20.00	977,892	I See footnote	—	—	(F4) This transaction was executed in multiple trades at prices ranging from $20.00 to $20.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
2	Common	Common Stock	2025-05-01	S	D	5,330	$20.08	980,062	I See footnote	—	—	(F2) This transaction was executed in multiple trades at prices ranging from $20.00 to $20.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.